Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Gains from Investment Securities (2020 - 2025)

Gain Therapeutics has reported Gains from Investment Securities over the past 6 years, most recently at $49868.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $49868.0 for Q4 2025, up 112.8% from a year ago — trailing twelve months through Dec 2025 was -$81659.0 (up 58.02% YoY), and the annual figure for FY2025 was $47549.0, down 98.49%.
  • Gains from Investment Securities for Q4 2025 was $49868.0 at Gain Therapeutics, down from $4.1 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for GANX hit a ceiling of $4.1 million in Q3 2025 and a floor of -$403938.0 in Q4 2021.
  • Median Gains from Investment Securities over the past 5 years was $71572.5 (2021), compared with a mean of $661205.7.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 1451.51% in 2021 and later soared 44875.65% in 2024.
  • Gain Therapeutics' Gains from Investment Securities stood at -$403938.0 in 2021, then surged by 84.41% to -$62993.0 in 2022, then skyrocketed by 315.42% to $135697.0 in 2023, then tumbled by 387.01% to -$389461.0 in 2024, then soared by 112.8% to $49868.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $49868.0 (Q4 2025), $4.1 million (Q3 2025), and $54945.0 (Q2 2025) per Business Quant data.